Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.
about
The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis BClinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues.Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.The HBV drug entecavir - effects on HIV-1 replication and resistanceInvestigational pharmacologic treatment for liver disease.Entecavir: a potent new antiviral drug for hepatitis B.Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.Agents in clinical development for the treatment of chronic hepatitis B.Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.Antivirals and antiviral strategies.Entecavir for the treatment of chronic hepatitis B.Review article: Nucleoside analogues for the treatment of chronic hepatitis B.Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection.Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial.Efficient genome replication of hepatitis B virus using adenovirus vector: a compact pregenomic RNA-expression unit.Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection modelEfficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system.Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture.Viral load in 1-day-old ducklings acutely infected with duck hepatitis B virus by different doses and routes of inoculation.Antiviral effects of PNA in duck hepatitis B virus infection model.Entecavir.Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels.Animal models for the study of hepatitis B virus infection.Development of a sensitive PCR inhibition method to demonstrate HBV nucleic acid inactivation.
P2860
Q27007019-1E5BB197-80C3-4FD0-8188-8A4B6E717B1CQ33206221-2C432BD4-F873-44E5-A62B-AB7BC76DE522Q33492413-9385836D-1F2C-4D73-BC1C-6887CA98678CQ33755065-EDFD4811-4C51-4504-BF85-0B90C2CC290FQ34584406-1EE0373D-4C37-41C3-B22A-4A475FE1BA3EQ34639926-66B3F883-7F46-4771-BA3D-A090CEAB8927Q34841865-6D487F32-2667-47F5-98FF-832CF07C533BQ35094702-BF750D31-E9A9-4285-ABC7-1CC48CDE5F7AQ35166065-D35C1C2B-1B08-4284-A426-E63BCD0F2639Q35185749-1F202C2D-7D12-41DD-A44C-56270A55EC63Q35735964-1731685C-994A-4D8D-9ECF-CE764AFE7ACBQ35889586-0F220FF0-CA20-4314-A013-EDA520CFB485Q35964745-C1B0FCFB-661B-4212-80AF-DA91B49D99F1Q35987869-80837B6F-7FAF-46DC-A8BC-79B1C5CD2BB9Q36314552-9E1530C1-22EA-4708-B52E-8247468D69B8Q37291331-875CEFE2-C13B-4EAB-A2D9-489D626BEEFAQ37356804-06E086E0-AD4B-4210-9BB6-98BE48EAC2EBQ37623537-E26F8379-9B70-40CE-A42B-E7C19A814922Q38071400-7A25B355-4FC3-44A7-AEBF-FA5EB9E09251Q39652624-B6C078A6-D555-43DE-A3B5-EC06654CF7B1Q39755479-8F221FBE-DC77-4587-8C72-8511C10A5E2CQ41930897-F403C822-183E-43AA-A86C-E7B1B2A562F9Q42041585-0D1BE8D9-4BF9-4AD9-8B62-27595843BB58Q45385702-432517B7-F1CE-4B3D-9456-3994A907DA55Q45399993-CA346DCE-8100-43EE-AD8D-2AF3B9336B50Q46631010-345A5536-C226-4E78-9A5F-42ECB1BF19E8Q46720186-6A2844D7-09B0-4A41-BC79-B1DDA5CED331Q52671153-7406CAA6-BAB6-42F8-A362-ACE06A787B80Q52842012-3F3273CB-44F7-45B5-98E7-15BCAD7EB21F
P2860
Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Potent efficacy of entecavir ( ...... hepatitis B virus replication
@nl
Potent efficacy of entecavir ( ...... hepatitis B virus replication.
@ast
Potent efficacy of entecavir ( ...... hepatitis B virus replication.
@en
type
label
Potent efficacy of entecavir ( ...... hepatitis B virus replication
@nl
Potent efficacy of entecavir ( ...... hepatitis B virus replication.
@ast
Potent efficacy of entecavir ( ...... hepatitis B virus replication.
@en
prefLabel
Potent efficacy of entecavir ( ...... hepatitis B virus replication
@nl
Potent efficacy of entecavir ( ...... hepatitis B virus replication.
@ast
Potent efficacy of entecavir ( ...... hepatitis B virus replication.
@en
P2093
P2860
P1476
Potent efficacy of entecavir ( ...... hepatitis B virus replication.
@en
P2093
Felix H Salazar
Mark A Winters
Patricia L Marion
Richard J Colonno
P2860
P356
10.1128/AAC.46.1.82-88.2002
P407
P577
2002-01-01T00:00:00Z